基于HPLC波长切换法对舒肝益脾液中7种成分的质量控制研究

摘 要 目的：建立HPLC波长切换法同时测定舒肝益脾液中7个成分。 方法: 色谱柱：Luna C18柱（250 mm×4.6 mm,5 μm）;流动相：乙腈 0.05％磷酸溶液,梯度洗脱;流速：0.9 ml·min-1;检测波长：345 nm（滨蒿内酯）、254 nm（毛蕊异黄酮苷、芒柄花苷、毛蕊异黄酮和芒柄花素）和210 nm（去氢茯苓酸和茯苓酸）;柱温：30 ℃,进样量：10 μl。结果: 滨蒿内酯、毛蕊异黄酮苷、芒柄花苷、毛蕊异黄酮、芒柄花素、去氢茯苓酸、茯苓酸7个成分的线性范围分别为6.09～152.25 μg·ml-1(r=0.999 9)、2.42～60.50 μg·ml-1(r=0.999 8)、1.61～40.25 μg·ml-1(r=0.999 6)、2.95～73.75 μg·ml-1(r=0.999 4)、6.88～172.00 μg·ml-1(r=0.999 9)、2.55～63.75 μg·ml-1(r=0.999 5)、2.09～52.25 μg·ml-1(r=0.999 9);平均加样回收率分别为98.96%（RSD=1.18%）,97.89%（RSD=1.41%）,97.18%（RSD=0.88%）,96.87%（RSD=0.97%）,99.32%（RSD=1.25%）,96.77%（RSD=0.86%）和98.55%（RSD=1.03%）（n=9）。结论: 本文建立的HPLC波长切换法同时测定舒肝益脾液中的7个成分,方法简便,可作为舒肝益脾液全面可靠的质量控制方法。     

湖州市第一人民医院药剂科 浙江湖州 313000

摘 要 目的：建立HPLC法同时测定复方羚角降压片中8种活性成分的含量。 方法: 采用HPLC波长切换法,色谱柱为Agilent ZORBAX Eclipse XDB C18(250 mm×4.6 mm,5 μm),流动相为甲醇(A) 0.06%磷酸溶液(B),梯度洗脱,流速为1.0 ml·min-1,检测波长为265 nm（紫丁香苷）、330 nm（咖啡酸、异迷迭香酸苷、迷迭香酸）、278 nm（黄芩苷、汉黄芩苷、黄芩素、汉黄芩素）,柱温为30℃,进样量为10 μl。 结果: 紫丁香苷、咖啡酸、异迷迭香酸苷、迷迭香酸、黄芩苷、汉黄芩苷、黄芩素、汉黄芩素分别在11.616～69.696 μg·ml-1,1.601～9.605 μg·ml-1,2.040～12.240 μg·ml-1,14.888～89.328 μg·ml-1,72.032～432.192 μg·ml-1,24.016～144.096 μg·ml-1,10.040～60.240 μg·ml-1,1.801～10.805 μg·ml-1(r为0.999 4～0.999 9）浓度范围内呈良好的线性关系;平均加样回收率分别为98.8%,99.7%,98.8%,98.0%,99.1%,99.3%,100.2%,97.4%,RSD分别为0.7%,0.7%,0.4%,0.6%,0.3%,0.5%,0.5%,0.7%（n=6）。 结论: 该方法简单、有效、准确,可用于复方羚角降压片中上述8种活性成分含量的同时测定。     

HPLC法测定米诺地尔洗剂含量及温度对含量影响的考察

摘 要 目的：建立高效液相色谱法同时测定化瘀祛斑胶囊中芍药苷、黄芩苷和黄芩素的含量。方法: 色谱柱为Agilent Zorbax SB C18柱（150 mm×4.6 mm,5 μm）;流动相为甲醇 0.1%磷酸溶液,梯度洗脱;流速为1.0 ml·min-1;检测波长为230 nm（0~15 min）,277 nm（15~45 min）;柱温为25℃;进样量为10 μl。结果: 芍药苷、黄芩苷和黄芩素的线性范围分别为1.295～25.890 μg·ml-1（r=0.999 9）、30.050～601.000 μg·ml-1（r=0.999 9）、1.874~37.480 μg·ml-1（r=0.999 9）,平均回收率分别为100.9%,100.3%,99.31%,RSD分别为0.92%,1.30%,0.89%。结论: 该法简便、快捷、结果准确、重复性好、实用性强,可以用于化瘀祛斑胶囊的质量控制。     

HPLC法同时测定参莲胶囊中7种生物碱成分的含量

摘 要 目的：建立RP HPLC双波长法同时测定参莲胶囊中氧化苦参碱、槐定碱、氧化槐果碱、苦参碱、槐果碱、粉防己碱、防己诺林碱7种生物碱含量。 方法: 采用Venusil XBP NH2（250 mm×4.6 mm,5 μm）色谱柱,以乙腈 0.01%醋酸铵水溶液为流动相梯度洗脱,流速为1.0 ml·min-1,检测波长为210 nm、280 nm。 结果: 氧化苦参碱、槐定碱、氧化槐果碱、苦参碱、槐果碱、粉防己碱、防己诺林碱线性范围分别为32.07～513.07 μg·ml-1（r=0.998 8）、37.90～606.40 μg·ml-1（r=0.999 2）、23.07～369.07 μg·ml-1（r=0.999 2）、52.37～837.87 μg·ml-1（r=0.999 7）、17.63～282.13 μg·ml-1（r=0.999 1）、5.30～84.80 μg·ml-1（r=0.999 5）、8.87～141.87 μg·ml-1（r=0.999 7）;平均加样回收率（n=9）为100.16%~102.84%（RSD≤2.0%）。5批样品中氧化苦参碱、槐定碱、氧化槐果碱、苦参碱、槐果碱、粉防己碱、防己诺林碱含量依次为9.18~9.69 mg·g-1、9.35~11.74 mg·g-1、6.73~7.09 mg·g-1、15.17~15.96 mg·g-1、5.03~5.33 mg·g-1、1.23~1.97 mg·g-1、2.48~2.74 mg·g-1。 结论: 所建立的多成分分析方法可用于参莲胶囊中7个生物碱成分的含量测定。     

HPLC法同时测定玉真散中天麻素、升麻素苷、5-O-甲基维斯阿米醇苷、欧前胡素、异欧前胡素的含量

摘 要 目的：建立HPLC法同时测定玉真散中天麻素、升麻素苷、5-O-甲基维斯阿米醇苷、欧前胡素、异欧前胡素含量。方法: 色谱柱为Phenomenex Gemini C18柱（250 mm×4.6 mm,5 μm）,柱温为25℃,流速为1.0 ml·min^-1 ,流动相为甲醇 水梯度洗脱,检测波长为230 nm,进样量为5 μl。结果: 天麻素在2.68~214.00μg·ml^-1范围内线性关系良好（r=0.999 9）,平均回收率为100.2％,RSD为0.9％（n=6）;升麻素苷在5.22~418.00 μg·ml^-1范围内线性关系良好（r=0.999 7）,平均回收率为99.9％,RSD为0.9％（n=6）;5-O-甲基维斯阿米醇苷在4.57~365.80 μg·ml^-1范围内线性关系良好（r=0.999 5）,平均回收率为99.7％,RSD为1.0％（n=6）;欧前胡素在5.22~417.20μg·ml^-1范围内线性关系良好（r=0.999 6）,平均回收率为99.0％,RSD为0.9％（n=6）;异欧前胡素在5.29~423.20μg·ml^-1范围内线性关系良好（r=0.999 8）,平均回收率为100.2％,RSD为0.8％（n=6）。结论: 该方法简单、准确,可同时测定5种成分的含量,可用于玉真散的质量控制。     

HPLC法同时测定骨筋丸胶囊中芍药苷、延胡索乙素和蛇床子素的含量

摘 要 目的：建立HPLC法同时测定骨筋丸胶囊中芍药苷、延胡索乙素和蛇床子素含量。方法: 采用Eclipse XDB C18（250 mm×4.6 mm,5 μm）色谱柱,以0.1%磷酸溶液（三乙胺调节pH至6.6） 乙腈为流动相进行梯度洗脱,流速为1.0 ml·min-1,柱温为30 ℃,检测波长为230 nm和280 nm。结果: 芍药苷、延胡索乙素和蛇床子素依次在9.56～33.65(r=0.999 8), 3.65～12.86(r=0.999 9)和5.81～20.45 μg· mL^-1(r=1.000 0)浓度范围内与峰面积呈良好线性关系,平均加样回收率分别为98.8%（RSD=1.1%）,98.4%（RSD=0.8%）和99.1%（RSD=1.4%）（n=6）。结论: 本方法简便、准确、重复性好,可用于该制剂的质量控制。     

HPLC法同时测定鼻炎愈合剂中阿魏酸、绿原酸和蒙花苷含量

摘 要 目的：建立HPLC法测定鼻炎愈合剂中阿魏酸、绿原酸和蒙花苷含量。方法: 以Agilent ZORBAX SB C18柱（250 mm×4.6 mm,5 μm）为色谱柱,流动相为乙腈 0.1%磷酸溶液,梯度洗脱,流速为1.0 ml·min-1,柱温30℃,检测波长326 nm。结果: 绿原酸、阿魏酸、蒙花苷分别在3.039 7~30.396 8 μg·ml-1 (r=0.999 7),3.999 9~39.999 4 μg·ml-1 (r=0.999 9),5.820 7~58.207 2 μg·ml-1(r=0.999 9)范围内与峰面积呈良好线性关系,其平均加样回收率分别为98.92%,100.81%,99.89%,RSD分别为1.00%,1.02%,0.99%（n=6）。结论: 该方法操作简便、准确、重现性好,可用于鼻炎愈合剂的质量控制。     

HPLC法测定枳实消痞丸中芸香柚皮苷、柠檬苦素、和厚朴酚及厚朴酚含量

摘 要 目的： 建立高效液相色谱法同时测定枳实消痞丸中芸香柚皮苷、柠檬苦素、和厚朴酚及厚朴酚含量的分析方法。方法: 色谱柱为岛津Shim-pack VP-ODS C18柱（250 mm×4.6 mm,5 μm）,流动相A为乙腈 甲醇(1∶2),流动相B为水,梯度洗脱,流速为1.0 ml·min^-1,柱温为30℃,进样量为20 μl;芸香柚皮苷检测波长为λ1=283 nm,柠檬苦素检测波长为λ2=210 nm,和厚朴酚、厚朴酚检测波长为λ3=294 nm。结果: 芸香柚皮苷、柠檬苦素、和厚朴酚、厚朴酚分别在5.26～105.20μg·ml^-1（r=0.999 8）、7.65～153.00 μg·ml^-1（r=0.999 4）、6.21～124.20 μg·ml^-1（r=0.999 3）、6.45～129.00 μg·ml^-1（r=0.999 6）范围内线性关系良好,平均加样回收率(n=6)分别为99.00％（RSD=0.77％）、98.17％（RSD=1.19％）、98.78％（RSD=0.86％）、97.90％（RSD=0.99%）。结论:该方法简便、准确、可靠,可用于枳实消痞丸的质量控制。     

GC法同时测定肚痛丸中6 种有效成分的含量

摘 要 目的：建立同时测定肚痛丸中6种成分含量的气相色谱方法。方法: 色谱柱为 HP 5柱 (30 m×0.32 mm,0.25 μm);采取程序升温,载气为氮气,流速为2.0 ml·min-1,进样量为1 μl,分流比为5∶1,进样口温度为280 ℃,检测器（FID）温度为300 ℃。结果:桂皮醛、乙酸龙脑酯、木香烃内酯、去氢木香内酯、厚朴酚、和厚朴酚分别在32.28~516.40 μg·ml-1（r=0.999 3）、27.06~433.00 μg·ml-1（r=0.999 2）、25.65~410.40 μg·ml-1（r=0.999 3）、26.10~417.60 μg·ml-1（r=0.999 3）、24.01~384.20 μg·ml-1（r=0.999 0）、18.32~293.10 μg·ml-1（r=0.999 4）范围内呈良好的线性关系;平均加样回收率分别为99.71%（RSD=0.67%）、99.34%（RSD=1.18%）、100.16%（RSD=0.34%）、100.40%（RSD=0.39%）、99.32%（RSD=1.22%）、99.58%（RSD=0.58%)(n=6）。结论:该方法操作简便,灵敏度高,准确度好,可为控制该制剂的质量提供依据。     

多波长HPLC法同时测定皮肤康洗液中5种有效成分的含量

摘 要 目的：建立多波长切换高效液相色谱法同时测定皮肤康洗液中芍药苷、甘草苷、甘草酸铵、大黄素和蛇床子素5种有效成分的含量。方法: 色谱柱为 Diamonsil C18柱(200 mm×4.6 mm,5 μm);流动相为乙腈 0.1%盐酸水溶液,梯度洗脱;流速为1.5 ml·min^-1;柱温为30℃;检测波长为232 nm(0～6 min,检测芍药苷)、277 nm(6～10 min,检测甘草苷)、254 nm(10 min以后,检测甘草酸铵、大黄素、蛇床子素）。结果: 芍药苷、甘草苷、甘草酸铵、大黄素和蛇床子素的线性范围分别为28.20～282.0 μg·ml^-1（r=0.999 7）、12.150～121.500 μg·ml^-1（r=0.998 8）、13.420～134.200 μg·ml^-1（r=0.999 5）、0.047～0.466 μg·ml^-1（r=0.999 9）、2.380～23.800 μg·ml^-1（r=0.999 9）,平均加样回收率分别为98.49%,99.00%,98.38%,97.36%,97.70%,RSD分别为0.71%,0.62%,0.85%,0.92%,0.78%（n=6）。结论:该方法简便、准确、灵敏度高、重复性好,可用于同时测定皮肤康洗液中上述5个有效成分的含量。     

Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics

Poloxamers are polyoxyethlyene, polyoxypropylene block polymers. The impurities of commercial grade Poloxamer 188, as an example, include low-molecular-weight substances (aldehydes and both formic and acetic acids), as well as 1,4-dioxane and residual ethylene oxide and propylene oxide. Most Poloxamers function in cosmetics as surfactants, emulsifying agents, cleansing agents, and/or solubilizing agents, and are used in 141 cosmetic products at concentrations from 0.005% to 20%. Poloxamers injected intravenously in animals are rapidly excreted in the urine, with some accumulation in lung, liver, brain, and kidney tissue. In humans, the plasma concentration of Poloxamer 188 (given intravenously) reached a maximum at 1 h, then reached a steady state. Poloxamers generally were ineffective in wound healing, but were effective in reducing postsurgical adhesions in several test systems. Poloxamers can cause hypercholesterolemia and hypertriglyceridemia in animals, but overall, they are relatively nontoxic to animals, with LD(50) values reported from 5 to 34.6 g/kg. Short-term intravenous doses up to 4 g/kg of Poloxamer 108 produced no change in body weights, but did result in diffuse hepatocellular vacuolization, renal tubular dilation in kidneys, and dose-dependent vacuolization of epithelial cells in the proximal convoluted tubules. A short-term inhalation toxicity study of Poloxamer 101 at 97 mg/m(3) identified slight alveolitis after 2 weeks of exposure, which subsided in the 2-week postexposure observation period. A short-term dermal toxicity study of Poloxamer 184 in rabbits at doses up to 1000 mg/kg produced slight erythema and slight intradermal inflammatory response on histological examination, but no dose-dependent body weight, hematology, blood chemistry, or organ weight changes. A 6-month feeding study in rats and dogs of Poloxamer 188 at exposures up to 5% in the diet produced no adverse effects. Likewise, Poloxamer 331 (tested up to 0.5 g/kg day(-1)), Poloxamer 235 (tested up to 1.0 g/kg day(-1)), and Poloxamer 338 (at 0.2 or 1.0 g/kg day(-1)) produced no adverse effects in dogs. Poloxamer 338 (at 5.0 g/kg day(-1)) produced slight transient diarrhea in dogs. Poloxamer 188 at levels up to 7.5% in diet given to rats in a 2-year feeding study produced diarrhea at 5% and 7.5% levels, a small decrease in growth at the 7.5% level, but no change in survival. Doses up to 0.5 mg/kg day(-1) for 2 years using rats produced yellow discoloration of the serum, high serum alkaline phosphatase activity, and elevated serum glutamicpyruvic transaminase and glutamic-oxalacetic transaminase activities. Poloxamers are minimal ocular irritants, but are not dermal irritants or sensitizers in animals. Data on reproductive and developmental toxicity of Poloxamers were not found. An Ames test did not identify any mutagenic activity of Poloxamer 407, with or without metabolic activation. Several studies have suggested anticarcinogenic effects of Poloxamers. Poloxamers appear to increase the sensitivity to anticancer drugs of multidrug-resistant cancer cells. In clinical testing, Poloxamer 188 increased the hydration of feces when used in combination with a bulk laxative treatment. Compared to controls, one study of angioplasty patients receiving Poloxamer 188 found a reduced myocardial infarct size and a reduced incidence of reinfarction, with no evidence of toxicity, but two other studies found no effect. Poloxamer 188 given to patients suffering from sickle cell disease had decreased pain and decreased hospitilization, compared to controls. Clinical tests of dermal irritation and sensitization were uniformly negative. The Cosmetic Ingredient Review (CIR) Expert Panel stressed that the cosmetic industry should continue to use the necessary purification procedures to keep the levels below established limits for ethylene oxide, propylene oxide, and 1,4-dioxane. The Panel did note the absence of reproductive and developmental toxicity data, but, based on molecular weight and solubility, there should be little skin penetration and any penetration of the skin should be slow. Also, the available data demonstrate that Poloxamers that are introduced into the body via routes other than dermal exposure have a rapid clearance from the body, suggesting that there would be no risk of reproductive and/or developmental toxicity. Overall, the available data do not suggest any concern about carcinogenesis. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used, and at what concentration, indicates a pattern of use. Based on these safety test data and the information that the manufacturing process can be controlled to limit unwanted impurities, the Panel concluded that these Poloxamers are safe as used.     

HPLC法测定抗妇炎胶囊中木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱

目的 采用高效液相色谱（HPLC）法同时测定抗妇炎胶囊中木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱10种活性成分。方法 采用InerSustain AQ-C₁₈色谱柱（250 mm×4.6 mm,5 μm）,流动相A：乙腈–无水乙醇（80∶20）,流动相B：0.1%磷酸溶液,梯度洗脱,检测波长220 nm,体积流量1.0 mL/min,柱温30℃,进样量10 μL。结果 木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱分别在2.69～134.50、1.95～97.50、0.63～31.50、0.86～43.00、11.95～597.50、0.59～29.50、6.08～304.00、4.85～242.50、1.66～83.00、19.79～989.50 μg/mL线性关系良好（r≥0.999 3）;平均回收率分别为99.11%、98.23%、96.95%、97.78%、100.02%、97.21%、99.66%、99.52%、98.81%、100.08%,RSD值分别为1.04%、1.23%、1.37%、1.65%、0.70%、1.28%、0.65%、0.81%、1.11%、0.63%。结论 建立的HPLC法可用于抗妇炎胶囊中10种活性成分的测定,作为抗妇炎胶囊质量控制方法。     

Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol

Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending.     

欧洲刺柏（Juniper）

活性成分与药理作用欧洲刺柏药用部位是其浆果，具有促水排泄、防腐、抗胃肠胀气和抗风湿作用，还可改善胃功能。用作促水排泄药可增加尿量（水丢失），但不增加钠排泄。成分萜品烯-4-醇可增加肾小球滤过率，但刺激肾。欧洲刺柏浆果对单纯疱疹病毒体外显示抗病毒活性，并具抗真菌活性。动物实验显示，欧洲刺柏浆果提取物具有堕胎、抗生育、抗炎、抗胚胎植入、降血压、升血压和降血糖作用。欧洲刺柏浆果油具有兴奋子宫的活性，以及利尿、胃肠道抗菌和刺激作用，该油对平滑肌有阻止解痉作用。     

Oral Presentations (LDD, LPES, LNM, LPAT, LNT, LPPT, LPM)

Probiotic microorganisms have been shown to provide specific health benefits when consumed as food supplements or as food components. The main problem of such products is the poor survival of the probiotic bacteria in the low pH of gastric fluid. However the use of synthetic excipients for enteric coating to prevent the exposure of microorganisms to gastric fluid is limited in food supplementary industry. Therefore the aim of this study was to develop an enteric coating formulation containing shellac as a natural polymer. Shellac possesses good resistance to gastric juice; the major disadvantage of this polymer is its low solubility in the intestinal fluid [1, 2]. Thus films containing different ratios of shellac and water-soluble polymers (sodium alginate, hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidon (PVP)) or plasticizers (glycerol and glyceryl triacetate (GTA)) were prepared in order to analyse the films’ melting temperatures (T_m), the changes in enthalpy (ΔH), their capability of taking up water, and their solubility in different media. The release characteristics of the films were studied by loading pellets with Enterococcus faecium M74 and coating them with formulations containing different amounts of shellac and polymer or plasticized shellac. Using dissolution tests, performed according to USP XXXI paddle method, the resistance of the coatings to simulated gastric fluid (SGF, pH 1.2) and the release of cells in simulated intestinal fluid (SIF, pH 6.8) was investigated.The trials showed that an increasing amount of plasticizer results in a decrease of T_m and ΔH of the films whereat glycerol had a superior plasticization effect to GTA. The compatibility of films made of water-soluble polymers and shellac was also concentration dependent. HPMC and PVP showed superior compatibility with shellac compared to sodium alginate, since films containing shellac and more than 10% [w/w] sodium alginate tended to separate into two phases. In the end five formulations containing shellac and either 5% [w/w] glycerol, 10% [w/w] PVP, 20% [w/w] PVP, 10% [w/w] HPMC, or 5% [w/w] sodium alginate emerged as feasible for enteric coating purposes.